Avalo Therapeutics
AVTX
18 hedge funds and large institutions have $72.3M invested in Avalo Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
35% more capital invested
Capital invested by funds: $53.6M → $72.3M (+$18.7M)
13% more funds holding
Funds holding: 16 → 18 (+2)
0.45% more ownership
Funds ownership: 64.23% → 64.68% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$394K |
| 2 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$282K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$169K |
| 4 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
+$113K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$78.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$597K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$74K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$32K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$22.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$22.5K |
AVTX Hedge Fund Activity: Q1 2018 in Review
18 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2018, worth a combined $72.3M — up 35% from $53.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AVTX positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $394K. The largest seller was Virtu Financial, cutting an estimated $597K.
- 18 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2018, up from 16 in Q4 2017.
- Funds reported $72.3M of Avalo Therapeutics stock for Q1 2018, up 35% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q1 2018 and 3 closed out, a net change of +2 holders.
- The largest Avalo Therapeutics buyer in Q1 2018 was Vanguard Group, an estimated $394K added.
- The largest Avalo Therapeutics seller in Q1 2018 was Virtu Financial, an estimated $597K sold.
Based on aggregated 13F filings for Q1 2018.